Abstract

Asymptomatic malaria, defined as the presence of Plasmodium parasites in human blood without clinical 
symptoms, is a major barrier to malaria elimination. These silent infections occur across all endemic settings and 
represent a significant infectious reservoir that sustains transmission despite control efforts. Epidemiological 
evidence demonstrates that both children and adults in high-transmission areas frequently harbor subpatent 
infections that evade standard diagnostics, thereby undermining surveillance and treatment programs. Advances 
in molecular diagnostics, such as PCR and LAMP have revealed the high prevalence of asymptomatic carriers, 
highlighting their role in maintaining parasite reservoirs through both wet and dry seasons. Asymptomatic 
malaria complicates public health strategies, given that carriers do not seek treatment yet contribute substantially 
to the onward transmission of Plasmodium species to Anopheles vectors. Control measures such as mass drug 
administration, mass testing and treatment, chemoprevention, and vaccination are being explored, though each 
faces challenges of feasibility, drug resistance, and ethical considerations. Emerging technologies, including 
parasite genomics, sensitive biomarkers, and longitudinal cohort studies, offer opportunities to refine detection, 
monitor transmission, and design targeted interventions. Addressing asymptomatic malaria through integrated 
approaches that combine diagnostics, community engagement, and policy support is essential to accelerating 
progress towards malaria elimination.